Acasti Pharma Valuation
| ACSTDelisted Stock | USD 3.37 0.01 0.30% |
At this time, the firm appears to be overvalued. Acasti Pharma shows a prevailing Real Value of $2.62 per share. The current price of the firm is $3.37. Our model approximates the value of Acasti Pharma from analyzing the firm fundamentals such as current valuation of 11.17 M, and Return On Equity of -0.19 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Acasti Pharma's price fluctuation is very risky at this time. Calculation of the real value of Acasti Pharma is based on 3 months time horizon. Increasing Acasti Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Acasti Pharma's intrinsic value may or may not be the same as its current market price of 3.37, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.37 | Real 2.62 | Hype 3.24 | Naive 3.28 |
The intrinsic value of Acasti Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Acasti Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Acasti Pharma helps investors to forecast how Acasti stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Acasti Pharma more accurately as focusing exclusively on Acasti Pharma's fundamentals will not take into account other important factors: Acasti Pharma Total Value Analysis
Acasti Pharma is presently projected to have valuation of 11.17 M with market capitalization of 36.5 M, debt of 11.56 M, and cash on hands of 38.39 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Acasti Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
11.17 M | 36.5 M | 11.56 M | 38.39 M |
Acasti Pharma Asset Utilization
One of the ways to look at asset utilization of Acasti is to check how much profit was generated for every dollar of assets it reports. Acasti Pharma shows a negative utilization of assets of -0.12 percent, losing $0.001162 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Acasti Pharma shows how unproductive it operates for each dollar spent on its assets.Acasti Pharma Ownership Allocation
The market capitalization of Acasti Pharma is $36.5 Million. Acasti Pharma retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Acasti Pharma Profitability Analysis
Net Loss for the year was (12.85 M) with profit before overhead, payroll, taxes, and interest of 120 K.About Acasti Pharma Valuation
The delisted stock valuation mechanism determines Acasti Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Acasti Pharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Acasti Pharma. We calculate exposure to Acasti Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Acasti Pharma's related companies.Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Acasti Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Acasti Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 9.5 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Acasti Stock
If you are still planning to invest in Acasti Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acasti Pharma's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges |